文献速递妇科肿瘤骨软组织肉瘤与黑色素瘤

青少年和年轻成人癌症的当前和未来全球负担:一项基于人群的研究

The current and future global burden of cancer among adolescents and young adults: a population-based study.
PubMed 文献 · Lancet Oncol · 2024-11-15

该研究基于GLOBOCAN数据库量化2022年及2050年全球15-39岁青少年和年轻成人癌症负担。2022年估计有1 300 196例新发病例和377 621例癌症相关死亡;女性发病ASR高于男性(52.9 vs 28.3),低收入国家病死率最高(57%)。预计至2050年全球负担增加约12%,低HDI地区病例和死亡均翻倍(增加102.3%)。

要点

  • 2022年全球15-39岁人群估计新发癌症1 300 196例,癌症相关死亡377 621例。
  • 女性发病ASR为52.9,男性为28.3;女性死亡ASR为13.1,男性为10.6。
  • 病死率从高收入地区的12%至低收入地区的57%不等。

核心结论

  • 青少年和年轻成人癌症发病率在发达国家最高,但转型国家结局最差且至2050年负担增加最大。

研究设计与样本

  • 基于GLOBOCAN数据库的基于人群的研究,量化2022年及2050年15-39岁人群癌症负担,涵盖所有癌症合并(除外非黑色素瘤皮肤癌)及33种特定癌症类型。
  • 使用死亡率与发病率比值估计病死率,按世界、区域、人类发展指数(HDI)和收入水平计算总体及性别特异性估计。
  • 通过将GLOBOCAN 2022率应用于联合国《世界人口展望2019年修订版》的性别特异性人口预测来估计2050年未来负担。

主要发现

  • 2022年估计1 300 196例新发病例和377 621例癌症相关死亡发生在青少年和年轻成人中。
  • 女性发病ASR为52.9,男性为28.3(女性为男性的1.9倍);女性死亡ASR为13.1,男性为10.6(女性为男性的1.2倍)。
  • 发病ASR在高收入国家最高,死亡ASR在低收入国家最高;病死率从高收入地区的12%至低收入地区的57%。
  • 在33种癌症类型中,乳腺癌是163个国家中最常诊断的癌症,宫颈癌是93个国家中最常诊断的癌症;乳腺癌和宫颈癌分别是163个和93个国家中癌症相关死亡的最常见原因;这些癌症的发病率和死亡率区域差异也最大。
  • 全球青少年和年轻成人癌症负担预计从2022年至2050年增加约12%,但极高HDI国家预计下降10.7%;增加预计绝大多数影响低HDI地区,病例和死亡负担均翻倍(增加102.3%)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Compared with children and older adults, the burden of cancer in adolescents and young adults (ages 15-39) is understudied. We aimed to quantify the global burden of adolescent and young adult cancer in 2022 and 2050, and explore patterns in incidence, mortality, and case fatality. METHODS: In this population-based study, we used the GLOBOCAN database to quantify the number of new cases and cancer-related deaths, and corresponding age-standardised incidence and mortality rates (ASRs; per 100 000 people aged 15-39 years), in adolescents and young adults. Estimates were quantified for all cancers combined, excluding non-melanoma skin cancer, and 33 specific cancer types. Case fatality was estimated using mortality-to-incidence ratios. Overall and sex-specific estimates were calculated at the world, regional, human development index (HDI), and income level. We estimated the future cancer burden by applying the GLOBOCAN 2022 rates to sex-specific demographic projections for the year 2050 using the UN World Population Prospects 2019 revision. FINDINGS: An estimated 1 300 196 cases and 377 621 cancer-related deaths occurred in adolescents and young adults in 2022. Incidence ASRs were 1·9-times higher and mortality ASRs were 1·2-times higher in females than in males (incidence ASR 52·9 vs 28·3; mortality ASR 13·1 vs 10·6). Although the incidence ASR was highest in the high-income countries, the mortality ASR was highest in the low-income countries; as a result, case fatality ranged from 12% in high-income settings to 57% in low-income settings. Of the 33 cancer types included in our analyses, breast or cervical cancer was the most frequently diagnosed cancer and cause of cancer-related death in 163 and 93 countries, respectively; incidence and mortality also varied the most by region for these cancers. Finally, the adolescent and young adult cancer burden globally is projected to increase by about 12% from 2022 to 2050, albeit with declines of 10·7% projected in very high HDI countries. The increase is expected to overwhelmingly impact low HDI settings, where the burden of both cancer cases and deaths is projected to double (a 102·3% increase). INTERPRETATION: Although the adolescent and young adult cancer burden incidence is highest in the most developed settings, transitioning countries have the poorest outcomes and will face the greatest increases in burden by 2050. These findings act as a reference to the global adolescent and young adult cancer community to inform cancer control priorities and decrease global inequities. FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Hughes T, Harper A, Gupta S, et al. The current and future global burden of cancer among adolescents and young adults: a population-based study. Lancet Oncol. 2024. PMID: 39557059. doi:10.1016/S1470-2045(24)00523-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。